By Ryan Allway | CannabisFN.com

Emerging research suggests that cannabinoids could be helpful in treating everything from chronic pain to inflammation to neurological conditions. These conditions represent multi-billion dollar markets, but the drugs are currently held back by government restrictions.

In this article, we will take a look at Vitality Biopharma Inc.’s (OTCQB: VBIO) recent breakthrough in developing a non-psychoactive THC molecule and what it means for pharmaceutical companies that are paving the way for federal approval of cannabis therapies.

Solving the THC Problem

The THC molecule has shown tremendous promise in recent clinical studies. For instance, GW Pharmaceuticals’ (NASDAQ: GWPH) Sativex® (nabiximols) is a formulated extract of the cannabis plant that contains both THC and CBD to treat pain and muscle spasticity. The problem with THC-based therapeutics is that they are psychoactive in nature, since the molecule binds with cannabinoid receptors, changing levels of dopamine and norepinephrine neurotransmitters.  This creates a “high”, and puts an upper limit on the dose of THC that can be administered for therapeutic uses.

Read this entire article at CannabisFN.com